Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of PRM-151 in Patients With Idiopathic Pulmonary Fibrosis

Next Previous
X
Search
Trial Profile

A Phase III Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of PRM-151 in Patients With Idiopathic Pulmonary Fibrosis

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 25 Jun 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Zinpentraxin alfa (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Registrational; Therapeutic Use
  • Acronyms STARSCAPE
  • Sponsors Promedior; Roche

    • Most Recent Events

    • 22 May 2024 Results assessing efficacy and safety of zinpentraxin alfa in Idiopathic Pulmonary Fibrosis patients,presented at the 120th International Conference of the American Thoracic Society
    • 21 Mar 2024 Status changed from completed to discontinued by the sponsor because the futility analysis outcome apparently showed that the study was not likely to meet the primary objective of the study. However, no new safety concerns were identified.
    • 18 Feb 2024 This trial has been discontinued in Portugal (End date:2023-02-10), according to the European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top